Rezzoug Francine, Huang Yiming, Tanner Michael K, Wysoczynski Marcin, Schanie Carrie L, Chilton Paula M, Ratajczak Mariusz Z, Fugier-Vivier Isabelle J, Ildstad Suzanne T
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 40202-1760, USA.
J Immunol. 2008 Jan 1;180(1):49-57. doi: 10.4049/jimmunol.180.1.49.
The use of tolerogenic cells as an approach to induce tolerance to solid organ allografts is being aggressively pursued. A major limitation to the clinical application of cell-based therapies has been the ability to obtain sufficient numbers and also preserve their tolerogenic state. We previously reported that small numbers of bone marrow-derived CD8+/TCR- graft facilitating cells (FC) significantly enhance hemopoietic stem cell (HSC) engraftment in allogeneic and syngeneic recipients. Although the majority of FC resemble precursor plasmacytoid dendritic cells (p-preDC), p-preDC do not replace FC in facilitating function. In the present studies, we investigated the mechanism of FC function. We show for the first time that FC significantly enhance HSC clonogenicity, increase the proportion of multipotent progenitors, and prevent apoptosis of HSC. These effects require direct cell:cell contact between FC and HSC. Separation of FC from HSC by transwell membranes completely abrogates the FC effect on HSC. p-preDC FC do not replace FC total in these effects on HSC function. FC produce TNF-alpha, and FC from TNF-alpha-deficient mice exhibit impaired facilitation in vivo and loss of the in vitro effects on HSC. Neutralizing TNF-alpha in FC similarly blocks the FC effect. The antiapoptotic effect of FC is associated with up-regulation of Bcl-3 transcripts in HSC and blocking of TNF-alpha is associated with abrogation of up-regulation of Bcl-3 transcripts. These data demonstrate a critical role for TNF-alpha in mediating FC function. FC may have a significant impact upon the safe use of chimerism to establish tolerance to transplanted organs and tissue.
将耐受性细胞作为诱导对实体器官同种异体移植产生耐受性的方法正在积极探索中。基于细胞的疗法临床应用的一个主要限制是能否获得足够数量的细胞并维持其耐受性状态。我们之前报道过,少量骨髓来源的CD8 + /TCR - 移植促进细胞(FC)能显著增强异基因和同基因受体中造血干细胞(HSC)的植入。尽管大多数FC类似于前体浆细胞样树突状细胞(p-preDC),但p-preDC在促进功能方面并不能替代FC。在本研究中,我们探究了FC发挥功能的机制。我们首次表明,FC能显著增强HSC的克隆形成能力,增加多能祖细胞的比例,并防止HSC凋亡。这些效应需要FC与HSC之间直接的细胞与细胞接触。通过Transwell膜将FC与HSC分离会完全消除FC对HSC的作用。p-preDC FC在对HSC功能的这些影响中并不能完全替代FC。FC产生肿瘤坏死因子-α(TNF-α),来自TNF-α缺陷小鼠的FC在体内的促进作用受损,对HSC的体外效应丧失。在FC中中和TNF-α同样会阻断FC的作用。FC的抗凋亡作用与HSC中Bcl-3转录本的上调有关,而阻断TNF-α与Bcl-3转录本上调的消除有关。这些数据证明了TNF-α在介导FC功能中起关键作用。FC可能对利用嵌合体安全建立对移植器官和组织的耐受性产生重大影响。